e-learning
resources
Stockholm 2002
Monday 16.09.2002
Lung cancer: clinical characteristics and prognosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of serum tumour markers in the lung cancer patients
D. Ediger, E. Kunt Uzaslan, M. Karadag, E. Gurdal Yuksel, E. Ege, N. Ozyardimci, O. Gozu, Z. Yavuz, F. Coskun (Bursa, Turkey)
Source:
Annual Congress 2002 - Lung cancer: clinical characteristics and prognosis
Session:
Lung cancer: clinical characteristics and prognosis
Session type:
Thematic Poster Session
Number:
1718
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Ediger, E. Kunt Uzaslan, M. Karadag, E. Gurdal Yuksel, E. Ege, N. Ozyardimci, O. Gozu, Z. Yavuz, F. Coskun (Bursa, Turkey). Evaluation of serum tumour markers in the lung cancer patients. Eur Respir J 2002; 20: Suppl. 38, 1718
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Serum tumor markers in lung cancer patients
Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies
Year: 2007
Tumor markers in bronchial secretions and serum in patients with lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Elevation of serum tumor markers in patients with interstitial lung disease
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Evaluation of serum levels of Sirtuin-1 in lung cancer patients
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004
Serum angiopoietins as a clinical marker for resected early lung cancer
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008
Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival.
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
The evaluation of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 323s
Year: 2005
Contribution of tumor markers to pretreatment staging of operable lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 360s
Year: 2003
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Serum hepcidin and iron are associated with non-small cell lung cancer stage
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Markers of angiogenesis in serum are correlating with disease progress in lung cancer
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept